Guide for patients & caregivers
Barrett's Esophagus on Endoscopy: What Does It Mean?
Barrett's esophagus on endoscopy explained: what the lining change means, how dysplasia is graded, typical surveillance intervals and questions to ask.
Prepared with AI assistance and checked against the cited sources. No independent clinician review has been completed. How we prepare articles
What does Barrett's esophagus on endoscopy mean?
Barrett's esophagus on endoscopy means the doctor saw an area where the normal pale pink lining of the lower esophagus (food pipe) has been replaced by salmon-coloured tissue that looks more like the lining of the intestine. The diagnosis is confirmed when biopsies show this change under a microscope. It is linked with long-term acid reflux and slightly raises the risk of a type of esophageal cancer, so it is usually monitored.
The American College of Gastroenterology (ACG) explains that a minimum of 1 cm of abnormal-looking lining is needed for the diagnosis. In the UK the condition is spelled Barrett's oesophagus. This guide explains the report and follow-up in general terms; it cannot interpret your own biopsy or say what your plan should be.
Symptoms that need urgent care or a sooner review
Barrett's esophagus itself usually causes no symptoms; reflux symptoms come from acid, not from the cell change. Some symptoms should not wait for a routine surveillance date.
The NHS advises an urgent GP appointment or NHS 111 (or your local urgent service) if you are being sick for more than 2 days or your poo is black or dark red. If you vomit blood, cannot swallow at all or have severe chest pain, seek emergency care through local services. Chest pain can also come from the heart, so do not assume it is reflux.
- New or worsening difficulty swallowing, or food sticking.
- Losing weight without trying.
- Vomiting, blood in your stool or black stools.
- Reflux symptoms that keep going despite treatment, or new chest pain.
- Pain in the throat or middle of the chest, especially when swallowing.
Is Barrett's esophagus cancer?
No. Barrett's cells are not cancer. NIDDK states that most people with Barrett's esophagus do not develop cancer, and that cancer, when it does occur, usually takes years to develop. The ACG patient page puts the chance of esophageal adenocarcinoma at less than 1 in 200 per year and says more than 90% of people with Barrett's will not develop cancer.
The reason for surveillance is that rare changes can be found early, when endoscopic treatment is possible. Risk estimates vary between studies and between individuals, so ask your specialist how they view your own risk rather than relying on a single average figure.
How is dysplasia graded on the biopsy?
Dysplasia means precancerous change in the cells. Pathologists usually report one of four categories, and the worse the dysplasia, the higher the risk. The ACG notes that low-grade dysplasia can be hard to diagnose and recommends a second pathologist review it. British Society of Gastroenterology (BSG) guidance recommends that all suspected dysplasia is reviewed by a second gastrointestinal pathologist.
- No dysplasia: Barrett's cells with no precancerous change. This is the most common and reassuring result.
- Indefinite for dysplasia: the pathologist cannot tell whether changes are dysplasia or inflammation from reflux. Guidelines suggest improving acid control and repeating the endoscopy in about 6 months.
- Low-grade dysplasia: early precancerous features. Once confirmed, options include treatment, often radiofrequency ablation, or closer monitoring.
- High-grade dysplasia: more advanced change. Once confirmed by an expert pathologist, endoscopic treatment to remove the Barrett's tissue is recommended.
How often is surveillance endoscopy done?
Intervals differ slightly between guidelines and are adjusted to the person. These are the figures stated by the sources below; your own team may set a different plan for good reasons.
- BSG (UK): every 2 to 3 years for long-segment Barrett's (3 cm or longer), and every 3 to 5 years for short-segment Barrett's (less than 3 cm) with intestinal metaplasia. The BSG gives a range so that the clinician can tailor the interval to the person.
- BSG (UK): for short-segment Barrett's without intestinal metaplasia or dysplasia, a repeat endoscopy with biopsies to confirm the finding; if that confirms no intestinal metaplasia, discharge from surveillance is encouraged.
- ACG (US): follow-up endoscopy for Barrett's without dysplasia is usually at 3 to 5 years.
- ACG (US): if confirmed low-grade dysplasia is monitored rather than treated, endoscopy is usually every 6 months in the first year and then yearly.
- BSG (UK): biopsies reported as indefinite for dysplasia should also be reviewed by a second gastrointestinal pathologist. The ACG advises better reflux control and a repeat endoscopy in about 6 months for this group.
How is Barrett's esophagus treated?
Without dysplasia, treatment is usually aimed at reflux symptoms rather than the Barrett's tissue itself. The ACG says most people are treated with a proton pump inhibitor (PPI), and NIDDK notes some studies suggest PPIs may lower the chance of high-grade dysplasia and cancer. The ACG notes that anti-reflux surgery is not used to lower the risk from Barrett's, and the BSG found insufficient evidence to support aspirin or similar medicines to prevent progression.
For dysplasia, endoscopic options include radiofrequency ablation, cryotherapy and endoscopic resection of visible lesions, usually at specialist centres. Do not stop or change a prescribed reflux medicine without talking to the prescriber. Smoking and extra weight around the waist are listed by NIDDK as risk factors, so they are worth discussing too.
Questions to ask your clinician
A follow-up conversation is a chance to cover cancer risk, the surveillance plan and symptom control, and to ask for a plain-language summary of each report. These questions can help you use that conversation.
- How long is my Barrett's segment, and what do the C and M measurements in the report mean?
- Did the biopsies show intestinal metaplasia, and what dysplasia grade was reported?
- If dysplasia was found, has a second or specialist pathologist reviewed it?
- When is my next endoscopy, and why was that interval chosen for me?
- Do I need to keep taking my reflux medicine, and is my current treatment controlling symptoms?
- Which symptoms should make me contact you before the next planned check?
- Would I be referred to a specialist Barrett's centre if treatment were needed?
How SameCase can help you prepare
On SameCase, patients and verified doctors share de-identified cases. Reading how others with a similar segment length or biopsy grade were followed up can help you notice questions you had not thought to ask, such as how a second pathology opinion was arranged.
Other people's cases cannot tell you your risk or replace your specialist's plan. Use them to prepare, then bring your questions and your own reports to your care team.
Keep your reports together
Keep each endoscopy report and pathology report, with dates, in one place. Surveillance plans depend on comparing results over time, and having them ready makes a review, a move between services or a second opinion easier. If reflux persists but your endoscopy was normal, a separate guide covers that situation.
Sources and further reading
- American College of Gastroenterology: Barrett's esophagus patient information (updated May 2024)
- NIDDK: Definition and facts for Barrett's esophagus
- NIDDK: Treatment for Barrett's esophagus
- NHS: Symptoms of oesophageal cancer and when to get urgent advice
- British Society of Gastroenterology: Guidelines on the diagnosis and management of Barrett's oesophagus (Fitzgerald RC, et al. Gut 2014, PDF)
For patients & caregivers
Share your case and learn from others
Learn from doctors and other people's cases to find a way forward with your health problem. New cases are public immediately. Don't add names or identifying details.